Bottmedical debuts its Naturaligner in the market

With the launch of Naturaligner, Bottmedical is a step closer to replacing existing aligners made from crude oil-based plastics. The Naturaligner is a CE certified and patented transparent aligner material system with a cellulose-based composite material – only using natural based plasticizers. In addition, the Naturaligner offers novel therapy approaches with unique comfort, thanks to having one of the thinnest material systems on the market. The product's biomechanics are currently under investigation in patients within a clinical study together with the University of Basel, Department of Biomedical Engineering.

Besides sustainability, biopolymers allow for embedding antibacterial agents that can be released for plague prevention, resulting in improved oral hygiene. Thus, for expanding its pipeline, Bottmedical plans to release a second-generation material system, which allows for preventing plaque formation and may help millions of caries-risk patients around the world. The Naturaligner 2.0 will be launched at the end of the year.

Parallel to the ongoing R&D studies, the startup has launched the Naturaligner in Switzerland, shipping from its headquarters in Basel. The company has also delivered its product to customers across Europe, and recently, it started its global expansion in Japan and Australia.

Commenting on the launch, Tino Töpper, Co-founder and CEO of Bottmedical said: “This is an important milestone for the founder of this idea but also for the current Bottmedical team who pushed the Naturaligner technology to that state.”

Founded in 2019 by Tino Töpper and Bekim Osmani as a start-up of the University of Basel, Bottmedical’s team has grown to ten people. So far, the company has raised CHF 1.5m equity capital and a total of CHF 0.9m in non-dilutive Innosuisse funding driving R&D University partnerships.

To step out of the start-up phase and prepare for the European scale-up, the company is currently preparing for the Series B investment round to boost manufacturing activities, scale and grow international sales and bring Naturaligner to more than one million patients in 2022, as envisioned by Ulrich Hoffmann, financial advisor and chairman of the Board of Directors at Bottmedical.